Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI
Status:
Completed
Trial end date:
2020-08-24
Target enrollment:
Participant gender:
Summary
Female inability to conceive a child. The purpose of this prospective randomized,
double-blinded, double dummy, two-arm cross-over study is to investigate the difference on
histological, transcriptional and immunological level in endometrium between 3x10mg
Dydrogesterone oral tablets and 3x200 mg Micronized progesterone intravaginal capsules for
the luteal support in egg cell donors. Beside that, the pharmacokinetics, the impact on the
peripheral immunology (by blood sampling) and the microbiota (by genital swabs) will be
investigated.
Phase:
Phase 4
Details
Lead Sponsor:
CRG UZ Brussel
Collaborators:
Abbott KU Leuven Universitätsklinikum Hamburg-Eppendorf